4//SEC Filing
LUNDEMOSE ANKER MD, PH.D, DSC 4
Accession 0001127602-10-016654
CIK 0000729922other
Filed
Jun 6, 8:00 PM ET
Accepted
Jun 7, 7:40 PM ET
Size
21.7 KB
Accession
0001127602-10-016654
Insider Transaction Report
Form 4
LUNDEMOSE ANKER MD, PH.D, DSC
Exec. VP & Pres. OSI Prosidion
Transactions
- Disposition to Issuer
Common Stock
2010-06-03$57.50/sh−17,892$1,028,790→ 1,675 total - Disposition from Tender
Common Stock
2010-06-03$57.50/sh−11,056$635,720→ 19,567 total - Disposition to Issuer
Stock Option (Right to Buy)
2010-06-03$57.50/sh−40,000$2,300,000→ 0 totalExercise: $48.30Exp: 2015-03-07→ Common Stock (40,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-06-03$57.50/sh−30,000$1,725,000→ 0 totalExercise: $38.01Exp: 2012-06-14→ Common Stock (30,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-06-03$57.50/sh−5,000$287,500→ 0 totalExercise: $29.77Exp: 2013-06-12→ Common Stock (5,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-06-03$57.50/sh−20,000$1,150,000→ 0 totalExercise: $37.74Exp: 2013-12-12→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-06-03$57.50/sh−22,000$1,265,000→ 0 totalExercise: $47.29Exp: 2014-12-11→ Common Stock (22,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-06-03$57.52/sh−48,000$2,760,960→ 0 totalExercise: $33.62Exp: 2015-12-15→ Common Stock (48,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-06-03$57.50/sh−20,000$1,150,000→ 0 totalExercise: $35.40Exp: 2019-12-14→ Common Stock (20,000 underlying)
Footnotes (2)
- [F1]Represents the number of unvested Restricted Stock Units that were canceled in exchange for a cash payment of $57.50 per unit in accordance with the Agreement and Plan of Merger, dated as of May 16, 2010, among OSI Pharmaceuticals, Inc., Astellas Pharma Inc., Astellas US Holding, Inc. and Ruby Acquisition, Inc.
- [F2]These stock options were canceled in exchange for a cash payment in accordance with the Agreement and Plan of Merger, dated as of May 16, 2010, among OSI Pharmaceuticals, Inc., Astellas Pharma Inc., Astellas US Holding, Inc. and Ruby Acquisition, Inc. The cash payment made with respect to each stock option equals the product of (x) the number of shares issuable upon the exercise of such option multiplied by (y) the excess, if any, of $57.50 over the exercise price per share for such option.
Documents
Issuer
OSI PHARMACEUTICALS INC
CIK 0000729922
Entity typeother
Related Parties
1- filerCIK 0001314821
Filing Metadata
- Form type
- 4
- Filed
- Jun 6, 8:00 PM ET
- Accepted
- Jun 7, 7:40 PM ET
- Size
- 21.7 KB